{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:53:25Z","timestamp":1785545605672,"version":"3.56.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:00:00Z","timestamp":1667865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:00:00Z","timestamp":1667865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Febuxostat is the drug used to treat hyperuricemia in patients with gout. Recently, the usage of Febuxostat has been controversial over the side effects in cardiovascular. The study aimed to comparatively analyze the risk of cardiovascular disease associated with febuxostat and allopurinol use in Korean patients with gout. A cohort study was conducted using national insurance claim data from the Health Insurance Review and Assessment Service (HIRA). Adult patients who were diagnosed with gout and prescribed febuxostat or allopurinol more than once from July 1, 2015, to June 30, 2018 were studied. The outcome was cardiovascular disease. Analysis was performed using Cox\u2019s proportional hazard model following 1:1 propensity score matching to estimate the hazard ratio with a 95% confidence interval. In total, 90,590 patients were defined as the final study cohort who had an average follow-up of 467\u00a0days, including 28,732 and 61,858 patients in the febuxostat and allopurinol groups, respectively. After the 1:1 propensity score matching, the risk of cardiovascular disease in the febuxostat group was significantly higher than in the allopurinol group (HR: 1.17; 95% CI: 1.10\u20131.24). In the sensitivity analysis, the risk of cardiovascular disease in the febuxostat group was significantly higher than in the allopurinol group (HR: 1.09; 95% CI: 1.04\u20131.15). However, further sensitivity analysis showed no statistically significant difference between the febuxostat group and allopurinol group after adjusting for cardiovascular disease history before the index date. Similarly, no statistically significant difference was found between the two drugs in the subgroup analysis. Febuxostat was not associated with a significantly increased risk of cardiovascular disease.<\/jats:p>","DOI":"10.1007\/s00296-022-05222-0","type":"journal-article","created":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T09:03:21Z","timestamp":1667898201000},"page":"265-281","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["`Risk of cardiovascular disease associated with febuxostat versus allopurinol use in patients with gout: a retrospective cohort study in Korea"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4974-5209","authenticated-orcid":false,"given":"Hoon","family":"Jeong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8486-4222","authenticated-orcid":false,"given":"Eunmi","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6027-3727","authenticated-orcid":false,"given":"Ahyoung","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0071-7493","authenticated-orcid":false,"given":"Myungsik","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0965-1323","authenticated-orcid":false,"given":"Bonggi","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,8]]},"reference":[{"key":"5222_CR1","unstructured":"JS P. Assessment of prevalence, incidence and risk factors associated with metabolic syndrome of gout using the National Health Insurance claim data: National Health Insurance Services Ilsan Hospital; 2017."},{"issue":"4","key":"5222_CR2","doi-asserted-by":"publisher","first-page":"344","DOI":"10.3904\/kjm.2018.93.4.344","volume":"93","author":"S Js","year":"2018","unstructured":"Js S (2018) New classification criteria and guideline for management of gout. Korean J Med 93(4):344\u2013350","journal-title":"Korean J Med"},{"key":"5222_CR3","doi-asserted-by":"crossref","unstructured":"MFDS Integrated pharmaceutical information system [https:\/\/nedrug.mfds.go.kr]. Ministry of Food and Drug Safety. [cited February 25, 2019]","DOI":"10.1080\/12294659.2020.1858585"},{"issue":"23","key":"5222_CR4","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1056\/NEJMoa050373","volume":"353","author":"MA Becker","year":"2005","unstructured":"Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA et al (2005) Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 353(23):2450\u20132461 (PubMed PMID: 16339094)","journal-title":"N Engl J Med"},{"issue":"11","key":"5222_CR5","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/art.24209","volume":"59","author":"HR Schumacher Jr","year":"2008","unstructured":"Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J et al (2008) Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 59(11):1540\u20131548 (PubMed PMID: 18975369)","journal-title":"Arthritis Rheum"},{"key":"5222_CR6","unstructured":"FDA. Center for Drug Evaluation and Research Application number: NDA 21\u2013856, Cross Discipline Team Leader(CDTL) Review 2009 [updated Accessed November 1, 2021]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/021856s000_CrossR.pdf."},{"issue":"13","key":"5222_CR7","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","volume":"378","author":"WB White","year":"2018","unstructured":"White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A et al (2018) Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med 378(13):1200\u20131210 (PubMed PMID: 29527974)","journal-title":"N Engl J Med"},{"key":"5222_CR8","unstructured":"FDA adds boxed warning for increased risk of death with gout medicine Uloric (febuxostat): US Food and Drug Administration; 2019 [updated February 21, 2019; cited 2021 July 12 ]. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-adds-boxed-warning-increased-risk-death-gout-medicine-uloric-febuxostat."},{"issue":"6","key":"5222_CR9","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/acr.24180","volume":"72","author":"JD FitzGerald","year":"2020","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM et al (2020) 2020 American college of rheumatology guideline for the management of gout. Arthritis Care Res 72(6):744\u2013760 (PubMed PMID: 32391934)","journal-title":"Arthritis Care Res"},{"key":"5222_CR10","unstructured":"Integrated pharmaceutical information system: Ministry of Food and Drug Safety; 2017 [cited 2021 November 1]. Available from: https:\/\/nedrug.mfds.go.kr."},{"issue":"5","key":"5222_CR11","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1517\/17425255.2014.904285","volume":"10","author":"HK Grewal","year":"2014","unstructured":"Grewal HK, Martinez JR, Espinoza LR (2014) Febuxostat: drug review and update. Expert Opin Drug Metab Toxicol 10(5):747\u2013758 (PubMed PMID: 24684266)","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"5222_CR12","doi-asserted-by":"publisher","first-page":"F710","DOI":"10.1152\/ajprenal.00454.2007","volume":"294","author":"LG Sanchez-Lozada","year":"2008","unstructured":"Sanchez-Lozada LG, Tapia E, Bautista-Garcia P, Soto V, Avila-Casado C, Vega-Campos IP et al (2008) Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 294(4):F710\u2013F718 (PubMed PMID: 18216151)","journal-title":"Am J Physiol Renal Physiol"},{"issue":"9\u201310","key":"5222_CR13","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.lfs.2007.12.010","volume":"82","author":"L Zhao","year":"2008","unstructured":"Zhao L, Roche BM, Wessale JL, Kijtawornrat A, Lolly JL, Shemanski D et al (2008) Chronic xanthine oxidase inhibition following myocardial infarction in rabbits: effects of early versus delayed treatment. Life Sci 82(9\u201310):495\u2013502 (PubMed PMID: 18215719)","journal-title":"Life Sci"},{"issue":"9","key":"5222_CR14","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.cardfail.2008.06.006","volume":"14","author":"X Xu","year":"2008","unstructured":"Xu X, Hu X, Lu Z, Zhang P, Zhao L, Wessale JL et al (2008) Xanthine oxidase inhibition with febuxostat attenuates systolic overload-induced left ventricular hypertrophy and dysfunction in mice. J cardiac failure. 14(9):746\u2013753","journal-title":"J cardiac failure."},{"issue":"5","key":"5222_CR15","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1097\/01.fjc.0000249961.61451.da","volume":"48","author":"M Hou","year":"2006","unstructured":"Hou M, Hu Q, Chen Y, Zhao L, Zhang J, Bache RJ (2006) Acute effects of febuxostat, a nonpurine selective inhibitor of xanthine oxidase, in pacing induced heart failure. J Cardiovasc Pharmacol 48(5):255\u2013263 (PubMed PMID: 17110808)","journal-title":"J Cardiovasc Pharmacol"},{"issue":"5","key":"5222_CR16","doi-asserted-by":"publisher","first-page":"718","DOI":"10.3346\/jkms.2017.32.5.718","volume":"32","author":"JA Kim","year":"2017","unstructured":"Kim JA, Yoon S, Kim LY, Kim DS (2017) Towards actualizing the value potential of korea health insurance review and assessment (HIRA) data as a resource for health research: strengths, limitations, applications, and strategies for optimal use of HIRA data. J Korean med sci 32(5):718\u2013728","journal-title":"J Korean med sci"},{"issue":"11","key":"5222_CR17","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1161\/CIRCULATIONAHA.118.033992","volume":"138","author":"M Zhang","year":"2018","unstructured":"Zhang M, Solomon DH, Desai RJ, Kang EH, Liu J, Neogi T et al (2018) Assessment of cardiovascular risk in older patients with gout initiating febuxostat versus allopurinol: population-based cohort study. Circulation 138(11):1116\u20131126","journal-title":"Circulation"},{"issue":"1","key":"5222_CR18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","volume":"70","author":"PR Rosenbaum","year":"1983","unstructured":"Rosenbaum PR, Rubin DB (1983) The central role of the propensity score in observational studies for causal effects. Biometrika 70(1):41\u201355","journal-title":"Biometrika"},{"issue":"12","key":"5222_CR19","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1093\/rheumatology\/kez189","volume":"58","author":"EH Kang","year":"2019","unstructured":"Kang EH, Choi HK, Shin A, Lee YJ, Lee EB, Song YW et al (2019) Comparative cardiovascular risk of allopurinol versus febuxostat in patients with gout: a nation-wide cohort study. Rheumatology 58(12):2122\u20132129 (PubMed PMID: 31098635)","journal-title":"Rheumatology"},{"issue":"7","key":"5222_CR20","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.3899\/jrheum.200307","volume":"48","author":"H Deng","year":"2021","unstructured":"Deng H, Zhang BL, Tong JD, Yang XH, Jin HM (2021) Febuxostat use and risks of cardiovascular disease events, cardiac death, and all-cause mortality: metaanalysis of randomized controlled trials. J Rheumatol 48(7):1082\u20131089 (PubMed PMID: 32801136)","journal-title":"J Rheumatol"},{"issue":"7","key":"5222_CR21","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/clc.23643","volume":"44","author":"L Gao","year":"2021","unstructured":"Gao L, Wang B, Pan Y, Lu Y, Cheng R (2021) Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta-analysis. Clin cardiol 44(7):907\u2013916","journal-title":"Clin cardiol"},{"issue":"10264","key":"5222_CR22","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/S0140-6736(20)32234-0","volume":"396","author":"IS Mackenzie","year":"2020","unstructured":"Mackenzie IS, Ford I, Nuki G, Hallas J, Hawkey CJ, Webster J et al (2020) Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet 396(10264):1745\u20131757 (PubMed PMID: 33181081)","journal-title":"Lancet"},{"issue":"1","key":"5222_CR23","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s10067-018-4396-4","volume":"38","author":"TLTA Jansen","year":"2019","unstructured":"Jansen TLTA, Janssen M (2019) Gout lessons from 2018: CARES, a direct comparison of febuxostat vs allopurinol, and CANTOS, IL1 blocker for cardiovascular risk minimisation. Clin Rheumatol 38(1):263\u2013265","journal-title":"Clin Rheumatol"},{"issue":"7","key":"5222_CR24","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.mayocp.2019.03.001","volume":"94","author":"CY Su","year":"2019","unstructured":"Su CY, Shen LJ, Hsieh SC, Lin LY, Lin FJ (2019) Comparing Cardiovascular Safety of Febuxostat and Allopurinol in the Real World: A Population-Based Cohort Study. Mayo Clin Proc 94(7):1147\u20131157 (PubMed PMID: 31272565)","journal-title":"Mayo Clin Proc"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-022-05222-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-022-05222-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-022-05222-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T08:06:52Z","timestamp":1675411612000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-022-05222-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,8]]},"references-count":24,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["5222"],"URL":"https:\/\/doi.org\/10.1007\/s00296-022-05222-0","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,8]]},"assertion":[{"value":"2 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study protocol was approved by the institutional review board (IRB) of the Korea Institute of Drug Safety and Risk Management (KIDS; KIDS-2019\u20134). Informed consent was waived by the IRB.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Since only anonymized data were used, informed consent by the insured individuals was not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}